Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Brain function

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44338   clinical trials with a EudraCT protocol, of which   7368   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    1,111 result(s) found for: Brain function. Displaying page 6 of 56.
    «« First « Previous 2  3  4  5  6  7  8  9  10  Next» Last»»
    EudraCT Number: 2018-002583-11 Sponsor Protocol Number: UM2018IMMUNOSABR2RLPL Start Date*: 2019-12-12
    Sponsor Name:Maastricht University Medical Centre
    Full Title: Phase II study examining the activity of L19-IL2 immunotherapy and stereotactic ablative radiotherapy in metastatic non-small cell lung cancer
    Medical condition: The trial will consist of one cohort of adult patients with Stage IV metastatic NSCLC
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10025044 Lung cancer LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: FR (Prematurely Ended) NL (Completed) BE (Completed) GB (GB - no longer in EU/EEA) IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2010-023362-44 Sponsor Protocol Number: ITAC 2 Start Date*: 2010-11-11
    Sponsor Name:Institute of oncology Ljubljana
    Full Title: ITAC 2 TRIAL: INTERMITTENT TKI AND CHEMOTHERAPY FOR PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER
    Medical condition: The study population consists of patients aged 18 years and older who have histologicaly or cytologicaly proven locally advanced or metastatic NSCLC with activating mutation of EGFR, chemonaive and...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SI (Completed)
    Trial results: (No results available)
    EudraCT Number: 2015-001593-18 Sponsor Protocol Number: 958 Start Date*: 2015-06-02
    Sponsor Name:Medizinische Universiät Wien
    Full Title: A pilot study to assess the influence of drug transporters on brain and organ distribution of erlotinib in humans
    Medical condition: Investigation in volunteers only
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2021-001029-32 Sponsor Protocol Number: PBI-200-101 Start Date*: 2022-01-18
    Sponsor Name:Pyramid Biosciences, Inc.
    Full Title: A Phase 1/2 Study of PBI-200 in Subjects with NTRK-Fusion-Positive Advanced or Metastatic Solid Tumors
    Medical condition: One of the following solid tumors which has progressed on or following at least one systemic therapy regimen administered for advanced or metastatic disease or for which no approved therapy exists:...
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029104 Neoplasms benign, malignant and unspecified (incl cysts and polyps) SOC
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) ES (Prematurely Ended) IT (Prematurely Ended) DK (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2014-002320-27 Sponsor Protocol Number: RPC01-301 Start Date*: 2014-11-21
    Sponsor Name:Celgene International II Sàrl (CIS II)
    Full Title: A Phase 3, multi-center, randomized, Double-Blind, double-dummy, active controlled, parallel group study to evaluate the efficacy and safety of RPC1063 administered orally to relapsing multiple scl...
    Medical condition: Relapsing Multiple Sclerosis
    Disease: Version SOC Term Classification Code Term Level
    19.0 10029205 - Nervous system disorders 10048393 Multiple sclerosis relapse PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: EE (Completed) PT (Completed) LV (Completed) SE (Completed) NL (Completed) BG (Completed) PL (Completed) ES (Completed) LT (Completed) HU (Completed) GB (Completed) HR (Completed)
    Trial results: View results
    EudraCT Number: 2019-005017-39 Sponsor Protocol Number: SGNTUC-016 Start Date*: 2021-01-08
    Sponsor Name:Seagen Inc.
    Full Title: Randomized, double-blind, phase 3 study of tucatinib or placebo in combination with ado-trastuzumab emtansine (T-DM1) for subjects with unresectable locally-advanced or metastatic HER2+ breast canc...
    Medical condition: Unresectable locally-advanced or metastatic HER2+ breast cancer
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10072740 Locally advanced breast cancer LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10027475 Metastatic breast cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned) DK (Trial now transitioned) FR (Trial now transitioned) AT (Completed) BE (Trial now transitioned) GB (GB - no longer in EU/EEA) NL (Trial now transitioned) SE (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2005-003944-68 Sponsor Protocol Number: EGF105084 Start Date*: 2006-02-15
    Sponsor Name:GlaxoSmithKline R&D Ltd
    Full Title: A Phase II Study of Lapatinib for Brain Metastases in Subjects with ErbB2-Positive Breast Cancer Following Trastuzumab based Systemic Therapy and Cranial Radiotherapy
    Medical condition: Progressive symptomatic or asymptomatic ErbB2 overexpressing breast cancer brain metastases.
    Disease: Version SOC Term Classification Code Term Level
    8.1 10027475 Metastatic breast cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) AT (Completed) DE (Completed) GB (Completed) BE (Completed) ES (Completed) GR (Completed) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2011-000123-33 Sponsor Protocol Number: RH EPOA-REHAB Start Date*: 2011-06-01
    Sponsor Name:King's College Hospital NHS Foundation Trust [...]
    1. King's College Hospital NHS Foundation Trust
    2. King's College London
    Full Title: Evaluation of the feasibility of modulating and measuring endogenous neurogenesis with erythropoietin (rhEPOα) to expedite recovery after stroke
    Medical condition: Stroke
    Disease: Version SOC Term Classification Code Term Level
    14.0 10029205 - Nervous system disorders 10042244 Stroke LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2016-004154-15 Sponsor Protocol Number: IEO523 Start Date*: 2017-10-11
    Sponsor Name:ISTITUTO EUROPEO DI ONCOLOGIA
    Full Title: A phase II, multicentric, open label, non-randomized, interventional study of Pembrolizumab in combination with Electrochemotherapy in patients with unresectable melanoma with superficial or superf...
    Medical condition: Unresectable melanoma with superficial or superficial and visceral metastases
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10053571 Melanoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2006-004451-38 Sponsor Protocol Number: A6181092 Start Date*: 2007-02-02
    Sponsor Name:PFIZER
    Full Title: A PHASE 2 EFFICACY AND SAFETY STUDY OF SU011248 IN PATIENTS WITH NON-SMALL CELL LUNG CANCER AND BRAIN METASTASES
    Medical condition: Non-Small Cell Lung Cancer NSCLC patients with brain metastases
    Disease: Version SOC Term Classification Code Term Level
    9.1 10059515 Non-small cell lung cancer metastatic LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed) FR (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2005-005859-18 Sponsor Protocol Number: SC05-03 Start Date*: 2006-06-13
    Sponsor Name:FONDAZIONE SANTA LUCIA
    Full Title: EFFECT OF MEMANTINE TREATMENT ON BRAIN FUNCTION AND MORPHOLOGICAL STRUCTURE IN PATIENTS WITH MODERATE TO SEVERE PATIENTS WITH ALZHEIMER S DISEASE A STRUCTURAL MR AND FMRI STUDY
    Medical condition: Moderate to severe Alzheimer s disease
    Disease: Version SOC Term Classification Code Term Level
    8.1 10009843 Cognitive deterioration LLT
    Population Age: Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2010-024659-10 Sponsor Protocol Number: 2010-024659-10 Start Date*: 2011-08-03
    Sponsor Name:Rigshospitalet
    Full Title: Can stimulation of the nNOS system in muscle disease with nNOS insufficiency improve heart and skeletal muscle function and cognition?
    Medical condition: Muscular dystrophy with nNOS insufficiency
    Disease: Version SOC Term Classification Code Term Level
    14.0 10028395 - Musculoskeletal and connective tissue disorders 10028301 Muscle disorder NOS LLT
    Population Age: Adults Gender: Male
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2013-000286-36 Sponsor Protocol Number: IGR2012/1950 Start Date*: 2014-04-02
    Sponsor Name:Gustave Roussy
    Full Title: A prospective phase II trial of cabazitaxel in male patients with chemotherapy pre-treated metastatic non-seminomatous germ-cell tumors
    Medical condition: patients with pre-treated metastatic and /or primary mediastinal non-seminomatous germ-cell tumors
    Disease:
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2020-005542-42 Sponsor Protocol Number: 2020/11 Start Date*: 2021-03-11
    Sponsor Name:Region Västerbotten
    Full Title: Intrathecal contrast-enhanced MRI for investigation of cerebrospinal fluid transportation
    Medical condition: Cerebrospinal fluid circulation disorder seen in clinically suspected idiopathic normal pressure hydrocephalus
    Disease:
    Population Age: Elderly Gender: Male, Female
    Trial protocol: SE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2017-005154-11 Sponsor Protocol Number: GECP17/05 Start Date*: 2018-05-31
    Sponsor Name:Spanish Lung Cancer Group (SLCG/GECP)
    Full Title: Phase II non-randomized study of Atezolizumab (MPDL3280A) in combination with Carboplatin Plus Pemetrexed in patients who are chemotherapy-naïve and have stage IV non-squamous non-small cell lung c...
    Medical condition: Atezolizumab combined with carboplatin and pemetrexed
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10025055 Lung cancer non-small cell stage IV LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2013-003306-45 Sponsor Protocol Number: CBKM120ZDE01T Start Date*: 2015-03-24
    Sponsor Name:Universitätsklinikum Tübingen
    Full Title: An open-label, uncontrolled, single arm phase II trial of BKM120 (Buparlisib) in patients with metastatic melanoma with brain metastases not eligible for surgery or radiosurgery
    Medical condition: metastatic melanoma with brain metastases
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-004244-28 Sponsor Protocol Number: BAN2401-G000-303 Start Date*: 2023-04-17
    Sponsor Name:Eisai Ltd.
    Full Title: AHEAD 3-45 Study: A Placebo-Controlled, Double-Blind, Parallel Treatment Arm, 216 Week Study with an Extension Phase to Evaluate Efficacy and Safety of Treatment With BAN2401 in Subjects With Prec...
    Medical condition: Preclinical Alzheimer's Disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10066571 Progression of Alzheimer's disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-000762-29 Sponsor Protocol Number: COLAL/11/2016 Start Date*: 2017-10-09
    Sponsor Name:MDM S.P.A.
    Full Title: CHOLINA ALPHOSCERATE INJECTION VERSUS CITICOLINE INJECTION IN ELDERLY PATIENTS WITH COGNITIVE IMPAIRMENT RESULTING FROM CEREBROVASCULAR EVENT
    Medical condition: Cognitive impairment resulting from cerebrovascular event.
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004852 10009846 Cognitive impairment LLT
    21.1 100000004852 10000374 Accident cerebrovascular LLT
    Population Age: Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2018-001027-40 Sponsor Protocol Number: ERIBRAIN-IPC2017-014 Start Date*: 2018-09-11
    Sponsor Name:Institut Paoli-Calmettes
    Full Title: ERIBRAIN - A phase II study of Eribulin in brain metastases from HER2-negative breast cancer pre-treated with anthracyclines and taxanes
    Medical condition: HER2-negative breast cancer with brain metastases
    Disease: Version SOC Term Classification Code Term Level
    20.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10055113 Breast cancer metastatic PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2016-002453-38 Sponsor Protocol Number: 15-102-14 Start Date*: 2017-01-17
    Sponsor Name:Nektar Therapeutics
    Full Title: A Phase 3 Open-Label, Randomized, Multicenter Study of NKTR-102 versus Treatment of Physician’s Choice (TPC) in Patients with Metastatic Breast Cancer Who Have Stable Brain Metastases and Have Been...
    Medical condition: Metastatic breast cancer with stable brain metastases
    Disease: Version SOC Term Classification Code Term Level
    20.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10055113 Breast cancer metastatic PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006198 Breast cancer recurrent PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) ES (Prematurely Ended) CZ (Completed) BE (Completed) PT (Completed) FR (Completed) HU (Completed) IT (Prematurely Ended)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 2  3  4  5  6  7  8  9  10  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu May 22 11:57:41 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA